No Detail Found!

Comparison of efficacy between long‑acting beta 2‑agonists (formoterol fumarate) and leukotriene‑receptor antagonists (montelukast) as add‑on therapy to inhaled corticosteroids (budesonide) in moderate persistent asthma

Author(s)
Sasikala Kumaravel Community Pharmacist, Al-Rimah Medical Centre Limited Liability Company, Sultanate of Oman,
Kingston Rajiah International Medical University, Kuala Lumpur, Malaysia,
Suchandra Sen Kovai Medical Center and Hospital College of Pharmacy, Coimbatore, Tamil Nadu, India
Abstract
Objective: This study was aimed to compare the efficacy between long-acting beta 2-agonists and leukotriene receptor antagonists as add-on therapy to inhaled corticosteroids in moderate persistent asthma. Materials and Methods: This study was carried out at the Kovai Medical Center and Hospital, in Coimbatore. The study protocol was approved by the Ethics committee of the Kovai Medical Center and Hospital. Patients with asthma in the outpatient respiratory department were included in the study. Out of 100 patients, 46 patients received the combination product, budesonide 400 µg and formoteral fumarate 6µg as an inhaled dose and this group was named group A. The other group had 44 patients and was prescribed oral montelukast 10 mg along with budesonide 400 µg as an inhaled dose. This group was called group B. The parameters recorded included, pulmonary function test reports, MBDS (Modified Borg's Dyspnea Scale). The quality of life was evaluated both before and after the treatment period by the SGRQ (St. George's Respiratory Questionnaire). Results: The two groups, group A and group B were assessed for pulmonary activity. The initial results of the score (MBDS) were 3.3 ± 0.12 and 3.2 ± 0.13 for group A and group B, respectively. Scores were reduced to 0.19 ± 0.08 and 0.35 ± 0.08 respectively after one month of therapy. For group A, the mean values for forced expiratory volume in one second (FEV1), peak expiratory flow (PEF) and forced vital capacity (FVC) before treatment were 1.4 ± 0.1, 3.2 ± 0.33 and 1.8 ± 0.18, respectively, whereas after treatment the values were 2 ± 0.14, 5.2 ± 0.41 and 2.4 ± 0.17. For group B the mean FEV1, PEV and FVC, before and after therapy were 1.2 ± 0.1 - 1.8 ± 0.17; 3.1 ± 0.3 - 5.4 ± 0.42; 1.8 ± 0.17 - 2.4 ± 0.22 respectively. Conclusions: In our conclusion, we suggest that a montelukast is as effective as formoterol fumarate for add-on therapy to budesonide in moderate persistent asthma. Hence, montelukast can be considered an alternate therapeutic option for such patients. The results of this study are expected to provide physicians with clinical evidence to help them make a rational decision when treating patients with moderate persistent asthma.
Publication Details
Page(s) 61-66
Published Journal: Archives of Pharmacy Practice, Volume: 5, Issue: 2, Year: 2014

Request the full text from PASTIC

Keywords
moderate persistent asthma, Montelukast, Budesonide, formoterol fumarate
References
Agarwal AN,Gupta D,Jindal SK .2002 .Development of a simple computer programme for spirometry interpretation. J Assoc Physicians India, 50 : 567-70.
RP Ahlquist .1948 .A study of adrenotropic receptors. Am J Physiol, 153 : 586-600.
Ahmed I,Sarnet JM .2000 .The natural history of asthma. Pediatric Asthma, : 41.
Arm JP,Horton CE,Spur BW,Mencia‑Huerta JM,Lee TH .2000 .The effects of dietary supplementation with fish oil lipids on the airways response to inhaled allergen in bronchial asthma. Am Rev Respir Dis, 139 : 1395-400.
Ash AS,Schild HO .1996 .Receptors mediating some actions of histamine. Br J Pharmacol Chemother, 27 : 427-39.
Ball DI,Brittain RT,Coleman RA,Denyer LH,Jack D,Johnson M .1991 .Salmeterol longa‑cting beta2a‑drenoceptor agonist: Characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol, 104 : 6657-1.
Balsbaugh TA,Chambers CV,Diamond JJ .2000 .Asthma controller medications: What do patients want. J Asthma, 36 : 591-6.
Balzano G,Fuschillo S,Gaudiosi C .2002 .Leukotriene receptor antagonists in the treatment of asthma: An update. Allergy, 57 : 16-9.
Barbee RA,Murphy S. .1998 .The natural history of asthma. J Allergy Clin Immunol, 102 : S65-72.
Barger G,Dale HH .2000 .Chemical structure and sympathomimetic action of amines. Am J Physiol, 41 : 195-9.
Bargmann KC,Lindemann L,Braun R .2004 .combination is superior to double dose fluticasone (500mcg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly, 134 : 50-8.
Barnes PJ .2005 .Inhaled glucocorticoids for asthma. New Engl J Med, 332 : 868-75.
Barnes PJ,Chung KF,Page CP .2008 .Inflammatory mediators of asthma: An update. Pharmacol Rev, 50 : 515-96.
Barnes PJ .2009 .Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol, 102 : 531-8.
Barnes PJ .2002 .Scientific rationale for combination inhalers with a long‑acting beta2 agonists and corticosteroids. Eur Respir J, 19 : 182-91.
Barnes PJ .2003 .Theophylline: New perspectives on an old drug. Am J Respir Crit Care Med, 167 : 813-8.
Barnes PJ .2004 .New drugs for asthma. Nat Rev Drug Discov, 3 : 831-44.
Batedman ED,Bantje TA,João Gomes M,Toumbis MG,Huber RM,Naya I .2003 .Combination therapy with single inhaler budesonide/formoterol compared with high does of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med, 2 : 2758-1.
Rajiah K,Sen S K . .Comparison of efficacy between long‑ acting beta 2‑ agonists (formoterol fumarate) and leukotriene‑ receptor antagonists (montelukast) as add‑ on therapy to inhaled corticosteroids (budesonide) in moderate persistent asthma. , : .
.2014 .. Arch Pharma Pract, 5 : 61-5.
0

Citations

0

Downloads

9

Views